Tag Archives: Amgen Inc.

Arrowhead Pharma obliterated after ditching Hep B candidate; oh, that’s right, biotechs are risky

Shares of Arrowhead Pharmaceuticals Inc. (Pasadena CA) cratered 69% to $1.44 last week (November 28 to December 2, 2016) after the company said it would stop developing all drugs being… Read more »

Cost of New Cholesterol Drugs Unsustainable Says JAMA Study; Ensuing Debate Rages

A new study from the University of California, San Francisco, using computer models of cardiovascular disease in American adults concludes that the price of a promising new class of cholesterol-lowering… Read more »

FDA Panel Supports Novartis Version of Amgen Arthritis Drug

By unanimous FDA panel vote, Novartis AG’s (Basel CHE) Enbrel (etanercept) biosimilar was approved across all of its U.S. licenses. The panel, which gives nonbinding advice to the agency, voted… Read more »

Rare Genetic Variation Associated with Lower-Than-Average Risk of Heart Disease

Researchers from Amgen Inc.’s (Thousand Oaks CA) deCode genetics unit said they have discovered a rare genetic variation that is associated with a 34% lower-than-average risk of heart disease, potentially opening up… Read more »

Cigna Signs “Results-Based” Deals on Costly Amgen, Sanofi Cholesterol Meds

Cigna Corp. (Bloomfield CT) signed deals that will pay the makers of two potent but pricey cholesterol-lowering treatments based on how well their customers respond to the medications, the health… Read more »